Scope
The IAP–NNF neonatal seizure chapter prioritizes EEG confirmation, stabilization and correction of reversible causes before or alongside antiseizure treatment. It distinguishes electroclinical from electrographic-only events and outlines first-line treatment, escalation and follow-up. This House summary covers the explicit diagnostic and acute-care recommendations. Its abbreviated drug-withdrawal statement is not sufficient to establish a complete stopping rule.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm seizures and distinguish mimics
- Use conventional continuous video EEG as the diagnostic standard in suspected neonatal seizures and high-risk babies. Amplitude-integrated EEG is a bedside screening tool with lower sensitivity and specificity; correlate either modality with video. [1]
- Seizures may have both clinical and EEG manifestations or be electrographic-only. Bedside observation can be misleading because movements such as jitteriness can mimic seizures. [1]
Stabilize and investigate the cause
- Secure airway, breathing and circulation, obtain intravenous access, check glucose and send calcium, electrolytes and a septic screen. Correct hypoglycaemia and electrolyte disturbances and treat infection before or alongside antiseizure medication. [1]
- Review antenatal and perinatal events, postnatal infection or intoxication, and family history of neonatal seizures, unexplained neonatal death or inherited metabolic/epilepsy disorders. Examine for dysmorphism, head-size abnormalities, bleeding, skin markers and neurological findings. [1]
- Laboratory assessment includes glucose, calcium, sodium, magnesium, a septic screen and lactate. The chapter advises CSF analysis with positive blood culture, clinical sepsis or recurrent/refractory seizures, and retaining a sample for metabolic investigation when indicated. [1]
- Investigate metabolic causes when seizures are refractory, follow an uneventful birth, occur with a family history of myoclonic seizures, or accompany progressive CNS deterioration. Consider a targeted genetic panel or exome sequencing when indicated or for refractory seizures. [1]
- Use cranial ultrasound for bedside screening in preterm or unstable babies. MRI is preferred after stabilization, typically on days 5–7 in the chapter; CT is listed when an urgent bleed is suspected. [1]
Correct reversible metabolic or infective triggers
- For hypoglycaemia, the chapter gives 10% dextrose 2 mL/kg intravenously over 2–3 minutes followed by an infusion at 6 mg/kg/min. [1]
- For hypocalcaemia, the stated initial treatment is 10% calcium gluconate 2 mL/kg slowly intravenously, followed by maintenance calcium. Sodium disturbances require fluid and sodium correction; suspected infection is treated according to unit policy after blood culture and CSF assessment. [1]
Use the stated antiseizure treatment sequence
- Phenobarbitone is first-line: load 20 mg/kg intravenously over 20 minutes. If seizures remain uncontrolled, repeat 10 mg/kg increments over 10–15 minutes, up to a cumulative 40 mg/kg. [1]
- The chapter lists phenobarbitone maintenance at 3–5 mg/kg/day in two divided doses only if seizures recur; a single episode without recurrence does not require maintenance in that table. [1]
- Levetiracetam or phenytoin are second-line options. Levetiracetam is preferred in cardiac disease; phenytoin or fosphenytoin is preferred when channelopathy is suspected. [1]
- For refractory seizures, the chapter uses midazolam with a bolus followed by infusion. Its table gives 0.1–0.2 mg/kg intravenously, then 0.1–0.4 mg/kg/hour, with vigilance for respiratory depression and hypotension and readiness to intubate. [1]
- Seek paediatric neurology input for difficult-to-control seizures. Pyridoxine is listed as an adjunct for refractory or atypical presentations with suspected vitamin-dependent epilepsy; newer agents such as lacosamide or topiramate belong in specialist-guided cases. [1]
Provide structured neurodevelopmental follow-up
- Enroll every infant with neonatal seizures in neurodevelopmental follow-up. Use a multidisciplinary approach with the neonatologist or paediatrician as the first contact, monitoring motor development, cerebral palsy, cognition, vision, hearing and recurrent seizures or epilepsy. [1]
Limitations and use
- This summary does not provide complete calcium infusion safety instructions, maintenance-fluid protocols, all second-line antiseizure doses or a full refractory-seizure algorithm. Specialist treatment and monitoring details must come from a complete protocol.
- The chapter’s abbreviated pre-discharge withdrawal statement does not define all conditions for seizure resolution or a complete drug-stopping rule. It must not be used to justify withdrawing treatment during ongoing seizures; no withdrawal algorithm is supplied here.
- The graphical management algorithm is not reconstructed. The stated prognostic percentages are not reproduced as individual outcome predictions.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Neonatal Seizures
Selected recommendation material consulted
Publication details
- Issuing organisation
- IAP / NNF
- Resource type
- Quick-reference guideline · House clinical summary
- Source setting
- India
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.